Thermo Fisher Introduces Integrated Cell Line Platform; CHOvantage GS Platform For Faster, Scalable Biologics Development

Thermo Fisher Scientific Inc. has introduced a next-generation, integrated cell line development platform designed to accelerate biologics development while ensuring regulatory compliance and scalability. The platform aims to help developers bring complex biologics and biosimilars to market faster amid growing global demand.

“Biologics developers face increasing pressure to deliver therapies faster while managing cost, quality and regulatory complexity,” said Sara Henneman, vice president and general manager of Thermo Fisher Scientific’s cell culture and cell therapy business. “With the CHOvantage GS CLD Kit, we’re helping customers compress development timelines, increase confidence in quality and lower overall costs through a royalty-free, clinical-stage licensing model that helps minimize barriers to market. This platform reflects our commitment to simplifying and standardizing biologics development workflows from research through commercial production.”

The newly launched Gibco™ CHOvantage™ GS Cell Line Development Kit enables the creation of high-performing CHO cell lines with protein yields of ≥7 g/L in fed-batch cultures. It significantly reduces development timelines by allowing stable cell pools to be generated in as little as four weeks and supporting clone selection within 14 weeks, streamlining the transition from early-stage research to commercial manufacturing.

BioFactura (a developer and manufacturer of high-value biosimilars and novel drugs) was a key pre-launch testing partner for the Gibco CHOvantage GS Cell Line Development Kit. Lead Cell Line Development Scientist Carson Brackna stated, "Combining transposon vectors and optimized media and feeds, the CHOvantage platform offered a robust, end-to-end cell line package while remaining user-friendly and yielding quality protein with high productivity on a tight schedule.”

With increasing regulatory scrutiny on product quality and comparability, along with the rise in biosimilar development driven by patent expirations, the platform is designed to enhance consistency, efficiency, and cost control. It simplifies complex manufacturing workflows while supporting large-scale production requirements.

“The CHOvantage GS CLD Kit is our newest example of how we are advancing cell line productivity and process consistency across the biologics lifecycle,” said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. “By integrating a transposon-based vector system with our Efficient-Pro media and feeds, we’re giving customers a reliable, high-quality, streamlined platform that helps to save time, reduces variability and supports scalability. Importantly, this harmonized workflow is designed to simplify tech transfer and enable a smoother transition from development to manufacturing.”

Additionally, the platform offers a flexible licensing model that eliminates clinical-stage royalties and provides research-use rights upon purchase. This approach improves cost predictability and enables a smoother path from development to commercialisation for biologics manufacturers.

Also Read

Thermo Fisher Launches Glacios 3 Cryo-TEM To Advance Structural Biology Research, With AI And Enhanced Lab Accessibility